ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2907

D1398G Variant Of Hepatocyte Growth Factor Receptor – A Potential Biomarker Of Severe Interstitial Lung Disease In African American Scleroderma Patients

Ilia Atanelishvili1, Tanjina Akter2, Richard M. Silver3 and Galina S. Bogatkevich2, 1Division of Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC, 2Department of Rheumatology, Medical University of South Carolina,Charleston,USA, Charleston, SC, 3Div Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: scleroderma and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Pathogenesis, Animal Models and Genetics: Pathogenesis of Systemic Sclerosis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Interstitial lung disease (ILD) is a major complication and leading cause of mortality in scleroderma (SSc, systemic sclerosis). The morbidity and mortality rates in African American scleroderma patients are higher when compared with SSc patients of other races. We previously demonstrated that hepatocyte growth factor (HGF) is reduced in BALF and plasma from African American SSc-ILD patients compared with white SSc-ILD patients. Moreover, in African American SSc fibroblasts the anti-fibrotic effects of HGF are compromised due to a deficiency in phosphorylation of the HGF receptor (cellular mesenchymal-epithelial transition factor, c-MET). The present study was undertaken to identify potential inhibitory mutations in c-MET gene extracted from lung fibroblasts with impaired phosphorylation of the HGF receptor.

Methods:

Lung tissue was collected postmortem from SSc patients who fulfilled the ACR criteria for SSc and had evidence of lung involvement. SSc-ILD was confirmed by histological examination of postmortem lung tissue. Lung fibroblasts were isolated using standard procedures. RNA samples from lung fibroblasts were prepared by QIAGEN RNeasy® kit; c-MET gene was extracted by QIAGEN OneStep RT-PCR Kit. The coding exons of c-MET were PCR amplified and sequenced on both strands on ABA Prism 377 Genetic Analyzer using taq dye terminator chemistry at our university’s DNA Sequencing Core. The sequence data were analyzed by BLASTN 2.2.18 using CCDS 47689. D1398G c-Met mutant was created using the QuickChange Site-Directed Mutagenesis XL kit from Stratagene; c-Met wild type and D1398G adenoviruses were generated by AdEasy Vector System, Quantum Biotechnology. HGF receptor phosphorylation, connective tissue growth factor (CTGF) and collagen content were studied by immunoblotting.

Results: We have identified six variants of c-Met unique for lung fibroblasts with non-functional HGF receptor. All of them are located in the C-terminus of the c-Met gene. We found that 100% of cell lines with non-functional HGF receptor carry the D1398G variant of c-Met gene; approximately 20% of all tested SSc lung fibroblasts contain C1379W and V1380G variants of c-Met gene; approximately 10% of cells with reduced HGF receptor function contain H1366P, L1351W, or E1350D variants of c-Met gene. None of these mutations was found in the c-Met gene isolated from SSc lung fibroblasts containing functional c-Met receptor. Lung fibroblasts isolated from African American SSc-ILD patients with D1398G variant of c-Met gene and normal lung fibroblasts transfected with D1398G c-Met mutant were characterized by limited effects of HGF on CTGF and collagen and by reduced HGF receptor phosphorylation on tyrosine 1238, 1252, and 1253.

Conclusion: D1398G variant of c-Met gene results in defective HGF signaling in lung fibroblasts. The occurrence of D1398G in African American SSc-ILD patients may explain in part a pathophysiologic link between African American race and poor pulmonary outcomes in SSc patients.


Disclosure:

I. Atanelishvili,
None;

T. Akter,
None;

R. M. Silver,

NIAMS-NIH,

2;

G. S. Bogatkevich,

NIAMS-NIH,

2.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/d1398g-variant-of-hepatocyte-growth-factor-receptor-a-potential-biomarker-of-severe-interstitial-lung-disease-in-african-american-scleroderma-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology